Treatment of ichthyosis lamellaris using a series of herbal skin care products family
Jazyk angličtina Země Itálie Médium print
Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie
PubMed
27498660
PII: 10
Knihovny.cz E-zdroje
- MeSH
- dospělí MeSH
- fytoterapie metody MeSH
- kůže účinky léků MeSH
- lamelární ichtyóza dietoterapie terapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- masti aplikace a dávkování terapeutické užití MeSH
- péče o kůži metody MeSH
- potravní doplňky * MeSH
- prospektivní studie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- multicentrická studie MeSH
- Názvy látek
- masti MeSH
Lamellar ichthyosis (LI) is a genetically heterogeneous group of disorders of keratinization that are inherited in an autosomal recessive fashion, occurring in approximately 1 in 300,000 live births. The treatment of the large, dark, plate-like scales that characterize the classic manifestation of the disease are still a challenge. The aim of this study was to evaluate the efficacy and tolerability of Dr. Michaels® skin-care products for the management of LI. A multi-centre European prospective study was conducted, including 10 patients (3 female/7 male) with lamellar ichthyosis, aged 38-54 years old (mean age: 46). Each patient had been treated with emollients plus other different systemic therapies, such as corticosteroids, Cyclosporin A or retinoids in the past. All patients were treated with Dr Michaels® product family including both topical and oral herbal supplements. The topical treatments used were the cleansing gel, activator formula and ointment. The oral medications were PSC 200, PSC 400 and PSC 900. Within 3 weeks of initiation of treatment, there were improvements observed on the skin including a reduction in scaling, fissuring, and intensity in erythema and pruritus with thinning of the hyperkeratotic plate. After 12-15 weeks, most of the plates and scales had been removed to reveal a normalised skin colour. Evidence of hair, eyelash and eyebrow growth was observed. There was partial nail resolution with a reduction in subungual hyperkeratosis. No adverse reactions were observed. Our patients showed excellent symptomatic response to treatment within a 14-week period, follow-up by an on-going regular assessment on a quarterly basis. The results show that Dr Michaels® product family is an effective and safe treatment option for LI.
Chair of Dermatology University of Rome G Marconi Rome Italy
Department of Nuclear Physics Sub nuclear and Radiation Guglielmo Marconi University Rome Italy
Dermatological Department University of Pisa Pisa Italy
PRO SANUM Ltd Sanatorium of Prof Novotný Štěpánská Prague 1 Czech Republic
Psoriasis and Skin Clinic Melbourne Australia
University B 1 S Group of Institutions Punjab Technical University Punjab India